Cargando…
Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker
INTRODUCTION: Plasma levels of amyloid-beta (Aβ) do not correlate well with different stages of Alzheimer's disease (AD) in cross-sectional studies. Measuring the changes in Aβ plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (...
Autores principales: | Oh, Esther S., Marano, Christopher M., Leoutsakos, Jeannie-Marie, Lee, Rebecca W., Rissman, Robert A., Smith, Gwenn S., Craft, Suzanne, Lyketsos, Constantine G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578701/ https://www.ncbi.nlm.nih.gov/pubmed/26413562 http://dx.doi.org/10.1016/j.dadm.2015.06.002 |
Ejemplares similares
-
Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020) -
Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017) -
The global Alzheimer's Association round robin study on plasma amyloid β methods
por: Pannee, Josef, et al.
Publicado: (2021) -
Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020) -
Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
por: O'Bryant, Sid E., et al.
Publicado: (2015)